Literature DB >> 15605283

Comparing alarms, desmopressin, and combined treatment in Chinese enuretic children.

Cherry Fai-Ngo Ng1, Sik-Nin Wong.   

Abstract

The objective of this multicenter randomized controlled trial was to compare the efficacy of enuresis alarms, oral desmopressin, and combined treatment in Chinese children with monosymptomatic primary nocturnal enuresis. We assigned 105 children aged 7-15 years to receive alarms (group 1, 35 patients), oral desmopressin 400 mug (group 2, 38 patients), or combined therapy (group 3, 32 patients) for 12 weeks; patients were then followed for 12 weeks after treatment. The wetting frequency decreased during treatment by 46%, 52%, and 73% in groups 1, 2, and 3, respectively. In groups 2 and 3, but not in group 1, there was rebound post treatment, but significant improvements persisted at 12 weeks. The complete and partial response rates were 22.9% and 20%, respectively in group 1, 42% and 10.5% in group 2, and 62.5% and 15.6% in group 3. By Kaplan-Meier analysis, group 1 had a significantly poorer response than groups 2 and 3. Of the responders, 20%, 60%, and 40% in groups 1, 2, and 3, respectively, relapsed after stopping treatment. In conclusion, enuresis alarms and/or oral desmopressin were less efficacious in Chinese than in Western societies. Desmopressin produced an immediate effect but relapses were common. Alarms took several weeks to produce a benefit, which was persistent on follow-up.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15605283     DOI: 10.1007/s00467-004-1708-5

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  27 in total

Review 1.  Intranasal desmopressin-associated hyponatremia: a case report and literature review.

Authors:  S A Bernstein; S L Williford
Journal:  J Fam Pract       Date:  1997-02       Impact factor: 0.493

2.  The child's construing of nocturnal enuresis: a method of inquiry and prediction of outcome.

Authors:  R J Butler; E J Redfern; W I Forsythe
Journal:  J Child Psychol Psychiatry       Date:  1990-03       Impact factor: 8.982

3.  Hyponatraemic convulsion secondary to desmopressin treatment for primary enuresis.

Authors:  D C Apakama; A Bleetman
Journal:  J Accid Emerg Med       Date:  1999-05

4.  The effect of desmopressin on short-term memory in children with primary nocturnal enuresis.

Authors:  D Müller; H Florkowski; K Chavez-Kattau; G Carlsson; P Eggert
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

5.  Oxybutynin, desmopressin and enuresis.

Authors:  T Nevéus
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

6.  Alarm treatment for childhood nocturnal enuresis: an investigation of within-treatment variables.

Authors:  R J Butler; J C Robinson
Journal:  Scand J Urol Nephrol       Date:  2002

7.  Improvements in self-concept after treatment of nocturnal enuresis: randomized controlled trial.

Authors:  M E Moffatt; C Kato; I B Pless
Journal:  J Pediatr       Date:  1987-04       Impact factor: 4.406

8.  Long-term treatment with desmopressin in children with primary monosymptomatic nocturnal enuresis: an open multicentre study. Swedish Enuresis Trial (SWEET) Group.

Authors:  K Hjälmås; E Hanson; A L Hellström; S Kruse; U Sillén
Journal:  Br J Urol       Date:  1998-11

9.  Reduction in nocturnal functional bladder capacity is a common factor in the pathogenesis of refractory nocturnal enuresis.

Authors:  C K Yeung; F K Y Sit; L K C To; H N Chiu; J D Y Sihoe; E Lee; C Wong
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

10.  Nocturnal enuresis and behavioral problems in adolescence: a 15-year longitudinal study.

Authors:  D M Fergusson; L J Horwood
Journal:  Pediatrics       Date:  1994-11       Impact factor: 7.124

View more
  8 in total

1.  Efficacy and safety of nasal desmopressin in the long-term treatment of primary nocturnal enuresis.

Authors:  Kenichi Kano; Osamu Arisaka
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

2.  A new checklist method enhances treatment compliance and response of behavioural therapy for primary monosymptomatic nocturnal enuresis: a prospective randomised controlled trial.

Authors:  Ahmet Metin Hascicek; Muhammet Fatih Kilinc; Yildiray Yildiz; Cem Nedim Yuceturk; Omer Gokhan Doluoglu
Journal:  World J Urol       Date:  2018-09-06       Impact factor: 4.226

3.  Monosymptomatic nocturnal enuresis in pediatric patients: multidisciplinary assessment and effects of therapeutic intervention.

Authors:  Simone N Fagundes; Adrienne Surri Lebl; Leticia Azevedo Soster; Guilherme Jorge Sousa E Silva; Edwiges Ferreira de Mattos Silvares; Vera H Koch
Journal:  Pediatr Nephrol       Date:  2016-12-17       Impact factor: 3.714

4.  Evaluation of Functional Bladder Capacity in Children with Nocturnal Enuresis According to Type and Treatment Outcome.

Authors:  Byeong Jin Kang; Jae Min Chung; Sang Don Lee
Journal:  Res Rep Urol       Date:  2020-09-15

5.  The efficacy of the addition of short-term desmopressin to alarm therapy in the treatment of primary nocturnal enuresis.

Authors:  Cuneyt Ozden; Ozdem Levent Ozdal; Binhan Kagan Aktas; Alper Ozelci; Serkan Altinova; Ali Memis
Journal:  Int Urol Nephrol       Date:  2008-03-05       Impact factor: 2.370

6.  Alarm interventions for nocturnal enuresis in children.

Authors:  Patrina Hy Caldwell; Miriam Codarini; Fiona Stewart; Deirdre Hahn; Premala Sureshkumar
Journal:  Cochrane Database Syst Rev       Date:  2020-05-04

7.  Efficacy of an enuresis alarm, desmopressin, and combination therapy in the treatment of saudi children with primary monosymptomatic nocturnal enuresis.

Authors:  Abul-Fotouh Abdel-Maguid Ahmed; Moamen Mohammed Amin; Mahmoud Mohammed Ali; Essam Abdel-Moneim Shalaby
Journal:  Korean J Urol       Date:  2013-11-06

8.  Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis.

Authors:  Carol Chiung-Hui Peng; Stephen Shei-Dei Yang; Paul F Austin; Shang-Jen Chang
Journal:  Sci Rep       Date:  2018-11-13       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.